Zafgen, Inc. (NASDAQ:ZFGN) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Wednesday, May 10th. Roth Capital initiated coverage on Zafgen in a research report on Thursday, April 20th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Cowen and Company reiterated a “hold” rating on shares of Zafgen in a research report on Friday, March 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $14.67.

Shares of Zafgen (NASDAQ:ZFGN) traded up 1.42% on Thursday, hitting $3.57. 82,211 shares of the stock traded hands. Zafgen has a 12 month low of $2.89 and a 12 month high of $7.09. The firm’s 50 day moving average is $3.80 and its 200-day moving average is $4.11. The company’s market cap is $97.72 million.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Equities analysts predict that Zafgen will post ($2.34) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Lifted to Sell at ValuEngine” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/08/zafgen-inc-zfgn-lifted-to-sell-at-valuengine.html.

In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The shares were purchased at an average cost of $4.40 per share, with a total value of $44,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.20% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the company. Parametric Portfolio Associates LLC raised its stake in shares of Zafgen by 55.8% in the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the last quarter. Nine Chapters Capital Management LLC acquired a new stake in shares of Zafgen during the first quarter worth about $170,000. Wells Fargo & Company MN raised its stake in shares of Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the last quarter. Federated Investors Inc. PA raised its stake in shares of Zafgen by 27.0% in the fourth quarter. Federated Investors Inc. PA now owns 129,661 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 27,533 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 5,794 shares during the last quarter. 52.00% of the stock is currently owned by hedge funds and other institutional investors.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.